JB
RNAM

Julian Baker’s Avidity Biosciences RNAM Stock Holding History

Julian Baker’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-625,000
Closed -$27.2M – 96
2025
Q3 		$27.2M Buy
+625,000
New +$25.3M 0.2% 43
2023
Q4 		– Sell
-166,347
Closed -$1.06M – 97
2023
Q3 		$1.06M Sell
166,347
-633,104
-79% -$5.45M 0.01% 96
2023
Q2 		$8.87M Sell
799,451
-204,600
-20% -$2.57M 0.05% 61
2023
Q1 		$15.4M Buy
1,004,051
+569,269
+131% +$12.5M 0.08% 42
2022
Q4 		$9.65M Buy
+434,782
New +$6.48M 0.06% 60

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Julian Baker's RNAM Position: Q4 2025 in Review

Julian Baker sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 625,000 shares — an estimated $27.2M sold.

Julian Baker first reported a position in RNAM in Q4 2022 and held it in 5 quarters. The position peaked at $27.2M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Julian Baker reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Julian Baker sold 625,000 Avidity Biosciences shares in Q4 2025, an estimated $27.2M.
  • Julian Baker first reported a position in Avidity Biosciences in Q4 2022 and held it in 5 quarters.
  • Julian Baker's Avidity Biosciences position peaked at $27.2M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Baker Bros. Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.